11 C-SCH442416 was reported in preclinical studies with rodents and primates to be the first nonxanthine radioligand suitable for the in vivo imaging of adenosine A 2A receptors with positron emission tomography (PET). The aim of the present work was to investigate the suitability of 11 C-SCH442416 for the in vivo quantification of A 2A receptors in human brain.
Introduction
Adenosine is an endogenous modulator of neurotransmission that acts via an interaction with Gprotein-coupled receptors in the central nervous system (CNS). Three major adenosine receptor subtypes have been identified: A 1 , A 2 and A 3 , with the adenosine A 2 receptors being subdivided into two further subtypes: A 2A and A 2B receptors. Adenosine A 2A receptors are abundant in the caudateputamen, nucleus accumbens, and olfactory tubercle [1, 2] . Although the roles of adenosine are not fully understood, it has been suggested that adenosine A 2A receptor activation may be involved in mediating a number of physiological functions in the CNS, including locomotion via regulation of the indirect striatal pathway to the internal pallidum and mood via its action on the ventral striatum. Potential therapeutic areas for agents acting at central A 2A receptors include schizophrenia, attention deficit hyperactivity disorder, anxiety disorders, depression, Huntington's disease, Gilles de la Tourette syndrome and Parkinson's disease.
For in vivo imaging studies using positron emission tomography (PET), several xanthine derivatives with A 2A receptor antagonist activity have been radiolabelled with the positron emitter carbon-11 ( C-KF1783 [3, 4] , 11 C-KF18446, 11 C-KF19631, 11 C-CSC [5] , 11 C-KW-6002 [6, 7] and 11 C-TMSX [8] [9] [10] have all been examined as markers of central A 2A receptors in preclinical models and humans. 11 C-KW-6002 showed potential as a PET ligand for quantifying striatal adenosine A 2A receptor function. However, cold KW-6002 partially blocked cerebellar binding of the tracer suggesting it was not a selective A 2A antagonist as this structure is reported to have low adenosine A 2A receptor density [7] . The A 1 selective antagonist KF15372 and the non-xanthine-type A 2A antagonist ZM 241385 both failed to block binding of 11 C-KW-6002 suggesting its cerebellar binding represented some other receptor class.
11
C-TMSX binding to A 2A receptors in the human brain has been reported [9, 10] . Binding potentials were low, ranging from 1.25 in the anterior putamen followed by the caudate (1.05) and thalamus (1.03) down to 0.46 in the frontal lobe [10] . In spite of numerous efforts to use labelled xanthine derivatives in PET imaging, their suitability as imaging biomarkers is limited by high nonspecific binding, relatively low signal-to-noise ratios and photoisomerization. Preclinical studies in rodents and primates suggest that 11 C-SCH442416 is a nonxanthine radioligand suitable for the in vivo imaging of adenosine A 2A receptors using positron emission tomography (PET) because of its high affinity and selectivity for adenosine A 2A receptors, good signal-to-noise ratio, and low levels of radioactive metabolite in the brains of nonhuman primates [11] [12] [13] [14] .
Here we present the results from the 11 Inclusion and exclusion criteria were chosen to ensure that a well-defined healthy subject population was included in the study. This included detailed medical history and complete physical examination, laboratory test results within normal range, normal vital signs, and normal or clinically acceptable 12-lead electrocardiogram (ECG). Exclusion criteria included any history or presence of clinically significant local or systemic infectious disease within 4 weeks prior to study drug administration, any significant medical disorder which would have required a physician's care, any history of seizures or autoimmune disorders, any history of mental instability; blood donation within 3 months before administration; history or presence of drug abuse; smoking more than 10 cigarettes or equivalent /day; subjects who have received radiation exposure (including x-rays) within 12 calendar months prior to the study; subjects with significant anatomical abnormalities noted on the MRI of the brain or any condition which would preclude MRI examination (e.g., implanted metal, severe claustrophobia); individuals who had evidence of only one patent arterial supply to the hand (Allen Test). All subjects had an indwelling venous cannula inserted into the median cubital vein of the forearm to inject the radioligand and also had an indwelling arterial cannula in the radial artery for the withdrawal of the blood samples.
This study was conducted in accordance with the Declaration of Helsinki Principles, ICH guidelines for Good Clinical Practice and after approval was obtained from the Research Ethics Committees at Central Middlesex and Hammersmith Hospitals, London; and the U.K. Administration of Radioactive Substances Advisory Committee (ARSAC). All subjects signed and dated an IEC-approved consent form before being enrolled into the study. All subjects were covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research.
PET/MRI scans
The radiotracer 11 C-SCH442416 was synthesized as previously described [11] . 364 MBq ± 11 MBq of 11 C-SCH442416 was injected by hand into an antecubital vein as a smooth bolus over 30 seconds (average injected volume was 1.9 mL ± 0.8 mL). Data for one subject could not be used because of an acquisition failure during the PET scan; thus data for four subjects were used in this study. The radiochemical purity was greater than 99% in all scans. The mass of co-injected cold SCH442416 was 2.13 µg ± 0.50 µg which is equivalent to a specific activity of 70. All PET scans were performed on the high-sensitivity Siemens/CTI scanner ECAT EXACT3D with an axial field of view of 23.4 cm and 95 reconstructed transaxial image planes [15] . To reduce the effect of activity outside the direct field of view in brain scans, the tomograph was equipped with annular side shielding [16] . A 5-minute transmission scan using a 137 Cs point source was carried out prior to each study for subsequent attenuation and scatter correction [17] . The 90-minute 3D dynamic emission scan was acquired in list mode. In the post acquisition frame rebinning, 28 time frames of increasing length were generated (30s background frame prior to the injection, then 1 15s-frame, 1 5s-frame, 4 10s-frames, 4 60s-frames and 17 300s-frames). The spatial resolution of the images reconstructed using filtered back projection algorithm with the ramp and Colsher filters set to Nyquist frequency with the following set of parameters: scatter correction was model based; attenuation correction was measured and segmented; reconstruction machine was SUN CPU with a zoom 2.5; spatial resolution of reconstructed images was 5.1 mm x 5.1 mm x 5.9 mm (full width at half maximum [FWHM]); and reconstructed voxel size was 2.10 mm x 2.10 mm x 2.43 mm.
Arterial whole blood activity was monitored continuously for the first 15 minutes of the scan with a bismuth germanate coincidence detector [18] and the blood flow rate set to 5 mL/min for a fine temporal sampling of the radioactivity peak in the blood following the bolus injection. As this was the first-in-man study with 11 C-SCH442415, ten discrete arterial blood samples were initially taken at 5, 10, 15, 20, 30, 40, 50, 60, 75 and 95 minutes into heparinised syringes from which the activity concentration of the whole blood and that of the plasma were measured in a NaI well counter. This blood sampling protocol was a first guess based on the published data obtained in rats [11] . As it will be seen in the Results section, it was observed in the first two scans that the in vivo metabolism of 11 C-SCH442415 in humans was actually faster than reported in animals, therefore from the third scan on the blood sampling protocol was adapted such that the ten discrete arterial blood samples were subsequently taken at 3, 7, 11, 15, 20, 30, 45, 60, 75 and 95 minutes.
For the analysis of the radiolabelled compounds in plasma, all discrete blood samples except the 20 min sample (for subjects 1 and 2) or the 60 min sample (for subjects 3 and 4) were centrifuged at 11,000 rpm for 2 min to separate the plasma from the sample. Then the plasma sample was filtered using a 0.2 µm diameter filter, and an aliquot of the filtered sample of 1 mL was analyzed using solidphase extraction with on-line reverse-phase HPLC radioactivity and UV detection [19] . The µ-Bondapak C 18 column (300 mm x 7.8 mm internal diameter, 10 µm particle size) was washed with the mobile phase, a mixture of ammonium formate (0.1 M) and acetonitrile (35:65, v/v) at a flow rate of 3 mL/min. The eluate was monitored for radioactivity and UV absorbance at 310 nm. Both detectors were linked to a PC based integrator which recorded the chromatogram and enabled the correction for 
Definition of regions-of-interest (ROIs)
For each subject, brain magnetic resonance images (MRI) were acquired with T 1 weighted RF spoiled gradient echo volume scans on a 1 Tesla Philips Medical Systems HPQ+ Scanner. The echo time T E was 6 ms, the repetition time T R was 21 ms, the flip angle was 35˚, yielding an image resolution of 1.6 mm x 1.6 mm x 1.0 mm (AP, LR, HF respectively).
The individual MR images were coregistered to the PET images summed from 1 to 30 min after tracer injection using an automated multiresolution optimization procedure [20] . Six ROIs were defined manually on the individual MR image: left and right putamen, left and right caudate and left and right thalamus. The cerebellum was defined using a probabilistic brain atlas template [21, 22] . Regional tissue time-activity curves were then generated from the dynamic images using the medical imaging software Analyze [23, 24] .
Data analysis
For the generation of the plasma input functions, the time course of the plasma-over-blood (POB) ratio, obtained from the first discrete arterial samples up to 20 min scan time, was fitted to an exponential approach to a constant value POB (t) = p 1  exp (-p 2  t) + p 3 with the three model parameters p 1 > 0, p 2 > 0 and p 3 > 0. For t = 0, the model function gives a POB value from the extrapolation of the measured data to zero.
POB (t=0) = p 1 + p 3 . The measurement of the arterial whole blood activity obtained from the continuous detector system [18] was then multiplied with that POB ratio to obtain a total plasma activity curve for the first 15 min of the scan. This curve was then combined with the discrete plasma activity concentration measurements at 20, 30, 40 (subjects 1 and 2 only), 45 (subjects 3 and 4 only), 50 (subjects 1 and 2 only), 60, 75 and 95 minutes to generate an input function describing the total plasma activity concentration for the entire scan.
The input function of the activity concentration due to unmetabolised 11 C-SCH442416 in plasma was then created by multiplying the total plasma activity input function with the function obtained from the fit of the model for the parent fraction in plasma to the nine measurements of the parent compound during the scan. For the description of the parent fraction (PF) in plasma during the entire scan an exponential approach to a constant value was used as the mathematical model PF (t) = (1 -q 2 ) · exp (-q 1 · t) + q 2 with the two model parameters q 1 > 0 and q 2 > 0. Therefore, the initial value was always constrained to one PF (t=0) = 1 . Finally, the temporal delay of the arrival of the radioactivity bolus at the peripheral sampling site relative to the brain was determined [25] .
Parameter estimates were obtained from fits of the measured tissue time-activity curves (no decay correction applied) minimizing the weighted sum of squares of the differences between the data and the model. The weights w for the individual data points were defined proportional to the reciprocal of the variance which was estimated from the scanner's rate of true coincidences T as
(for frame i = 1, 2, 3, …) with L as the length of the frame [26] .
Spectral analysis [27] of the regional tissue time-activity curves was performed with non-decay corrected data, using a library of 800 basis functions logarithmically spaced between the time constant of the radioactive decay of 11 C (λ= 5.663 x 10 -4 s) and 10 s -1 .
The binding potential of the nondisplaceable binding BP ND [28] was then calculated indirectly from the regional estimates of the total volume of distribution
using V T of the cerebellum as an estimate of the free and nonspecifc binding of 11 C-SCH442416 throughout the brain. Cerebellum was previously reported from human autoradiographic studies as a region with a negligible density of A 2A receptors.
Spectral analysis [27] was also performed at a voxel level with the nonnegative least squares algorithm [29] as published in the Netlib (http://www.netlib.org/lawson-hanson) using 100 basis functions for the computational cost which were logarithmically spaced between the time constant of the radioactive decay of 11 C β min = 5.663·x 10 -4 s -1 (log 10 β min = -3.247) and β max = 1 s -1 (log 10 β max = 0). For each peak in the spectrum (peak position β i , peak height α i ), the contribution to the volume of distribution was obtained as
. From the set of n peaks the total volume of distribution V T was calculated as
(excluding the peak representing the fractional blood volume).
All calculations were performed using Matlab ® (The MathWorks, Inc., Natick, MA, USA) on Sun Ultra TM 10 workstations (Sun Microsystems, Inc., Santa Clara, CA, USA).
Results and Discussion

Input function
As reported from previous animal studies [11, 13] , blood 11 C-SCH442416 was initially distributed only in the plasma. A shows the time courses of the ratio of the plasma activity concentration over the whole blood activity concentration for all four subjects. With H as the haematocrit measured in the baseline blood sample before injection of the radioligand, the plasma-over-blood ratio extrapolated to . Over the first 30 minutes of the scan, the plasma-over-blood activity ratio decreased. At later times the plasma-over-blood activity ratio rose again, consistent with the appearance of polar radiolabelled metabolites in the blood plasma. The radiochromatograms of the plasma radioactivity showed a minor polar radioactive component (retention time about 4.2 min) and a main component (retention time of 7.5 min) which was identified as 11 C-SCH442416 as it co-eluted with the same retention time as the unlabelled authentic standard of SCH442416. The other radioactive compounds observed in plasma were more polar than 11 C-SCH442416 but were not identified. The percentage of radioactive metabolites was observed to increase with time (B). The fraction of unmetabolized parent tracer in blood plasma averaged over the four subjects decreased from 87% at 3 minutes to about 41% at 15 minutes and 15% at 95 minutes post-injection, respectively. Therefore, the peripheral metabolism of 11 C-SCH442416 is faster in humans than previously reported in rats [11] and in a macaca nemestrina [13] .
Tissue activity
There was rapid uptake of 11 C-SCH442416 in all brain regions. Inspection of the integral PET image from 1 to 30 minutes after injection reveals that the A 2A receptor rich striatal regions show higher activity than cortical brain areas and the cerebellum. This shows that in all four subjects the tissue response functions reached a maximum on average at 3 minutes post bolus injection of the tracer. A relatively rapid reversible component of uptake was combined with a slower and apparently irreversible component with considerable inter-subject variability. In Subjects 1 and 3 (left) the rising plateau of irreversibly bound activity was much more marked than in Subjects 2 and 4 (right) whose tissue TACs showed mainly reversible characteristics reaching a nearly constant activity concentration at the end of the scans for all considered ROIs. The between subject variability in this cohort of four subjects is quite pronounced which complicates production of a coherent model describing the observed kinetics across regions and subjects. 
Kinetic analysis
Applying traditional compartmental modelling, two configurations could describe the observed kinetics: a two-tissue, three rate constants sequential compartment model (A) or a two-tissue, three rate constants parallel compartment model (B). The sequential model (A) has been previously used to describe the irreversible binding of ligands such as 11 C-N-methylspiperone [30, 31] . There, the irreversible uptake of the ligand as specified by the rate constant k 3 was the parameter which characterised the binding to the dopamine D 2 receptor sites. In other words, the specific binding of the radioligand to the receptor sites was represented by the irreversible accumulation of the radioactivity in tissue.
This means that the PET time-activity curve in a receptor-rich region differed from the time-activity curve in a region with lower receptor density by the slope of the irreversible binding component. Visual inspection of the time-activity curves reveals that within one subject there is no such slope difference between the regions. In fact the decay-corrected tissue time-activity curves of the different regions for one subject are almost parallel after 40 min. On the other hand, different slopes of the timeactivity curves are observed between the four subjects. Therefore, the parallel compartmental model (B) was proposed to describe the kinetics of 11 C-SCH442416 in brain tissue. The parameter K 7 in this model is not related to specific binding of the radioligand to the receptor sites but is used to characterise nonspecific uptake. Spectral analysis [27] was used as a method to separate the various components of the tissue response curves representing irreversible binding, reversible binding, and a fast blood volume component.
Regional parameter estimates for all four subjects are presented. The height of the irreversible spectral analysis peak in one subject is fairly constant across studied brain regions; however, there are considerable differences between the four scanned subjects in their irreversible uptake. The volumes of distribution V T of the reversible peaks are lowest in the cerebellum which is devoid of A 2A receptors in humans, intermediate in the thalamus and highest in the regions comprising the striatum. This rank order is consistent with the known A 2A receptor distribution in the human brain [2] .
Therefore, the V T of the reversible binding of 11 C-SCH442416 appears to be correlated with the binding to the A 2A receptor sites. Assuming that the V T describes free, non-specifically and specifically bound ligand in the brain tissue, estimates of regional binding potential BP ND were calculated indirectly from the ratio of the target region over the cerebellar minus one and are listed in the last column. Mean binding potentials averaged across the left and right ROIs of the four subjects were calculated as 2.47 (putamen), 1.59 (caudate) and 0.53 (thalamus).
Furthermore, spectral analysis was also applied on the pixel level. In histograms of the volume of distribution are shown for two regions, the cerebellum and the striatum (combination of the putamen and caudate regions). The single peak in the fastest histogram bin on the right hand side at β max = 1 s -1 (log 10 β max = 0) represents the fractional blood volume. The difference between the histograms of the receptor-rich striatum and that of the cerebellum outlines the contribution of the specific binding to the total volume of distribution. Note that the irreversible peak in the leftmost bin at β min = 5.663·x 10 -4 s -1 (log 10 β min = -3.247) cannot been displayed as it corresponds to an infinite volume of distribution. corresponding with the left end of the spectrum log 10 β min = -3.247.
Discussion
In this first-in-man study, the novel nonxanthine radioligand 11 C-SCH442416 for the measurement of A 2A receptor binding revealed two properties that set it aside from the majority of receptor ligands commonly used in molecular imaging.
First, the in vivo metabolism of 11 C-SCH442416 was found to be faster in humans than previously reported in rats [11] and in macaca nemestrina [13] . This had not been expected when the blood sampling and metabolite analysis protocol was originally devised therefore making a later adjustment of the scanning protocol necessary. This finding is also in contrast to what is observed with most PET radiotracers which are usually metabolised more rapidly in rodents than in man.
Second, most radioligands which are used in PET for the quantification of receptor availability bind reversibly within the time course of a PET scan which is typically two hours or less for a 11 C labelled compound. There are also examples of PET neuroreceptor studies with tracers which effectively bind irreversibly during the PET scan, 11 C-N-methylspiperone [30, 31] being a prominent example.
However, it is unusual for an irreversibly binding component to represent non-specific uptake which does not vary between brain regions with high and low concentration of binding sites.
From our data it is not clear what this slow, region independent and subject specific irreversible brain uptake reflects. The possibility that a brain penetrating, slowly accumulating and nonspecifically binding radiometabolite of 11 C-SCH442416 exists cannot be excluded unless brain tissue samples are investigated for their radiolabelled entities. However, the absence of radiolabelled compounds in the human plasma samples that are lipophilic and therefore would be considered to be likely to cross the blood-brain barrier by passive diffusion did not provide any support for the hypothesis that the slow and apparently irreversible tissue uptake is caused by the brain accumulation of a radiolabelled metabolite of 11 C-SCH442416. As the radiochemical purity of 11 C-SCH442416 prior to injection was always measured to exceed 99%, there is also no suggestion that co-injected radiolabelled impurities were responsible for the observed accumulation of nonspecifically binding radiolabel in the human brain.
Despite this difficulty, we have used the standard approach of quantification for reversibly binding radioligands [28] However, if 11 C-SCH442416 is for example to be used to estimate the A 2A receptor occupancy by a drug with affinity to these receptors in a dual PET scan paradigm (one tracer alone baseline scan and one blocked scan after drug administration), then the BP ND as calculated here can still be used for the calculation of the per cent occupancy with the equation
provided that the assumptions that are usually made in those studies, such as unchanged nondisplaceable binding between the two conditions [33] , are met.
In this report, spectral analysis [27] was used to analyse the kinetics of 11 C-SCH442416 brain uptake at a regional and also a voxel level. This had the advantage over choosing a compartmental model that no a priori assumptions on the number of tissue compartments needed to appropriately describe the kinetics or on the reversibility of the binding had to be made. From the results obtained with spectral analysis, two compartmental models could be used to equally fit the data. These two model structures are mathematically indistinguishable, i.e. a given data set will be fitted by the model equations with the same residual sum of squared errors. The following correspondences allow the conversion of the microparameters between the two models:
However, only the model structure of B provides estimates of the total volume of distribution with a single rate constant K 7 that is equivalent to the height of the irreversible peak in spectral analysis reported in the second column.
PET scans in more than four subjects studied here, and more than one scan per subject are needed to better characterise the pronounced intersubject variability in the binding of 11 C-SCH442416, and to characterize also the radioligand intrasubject variability. Furthermore, it is crucial to perform PET scans with 11 C-SCH442416 with subtype selective A 2A receptor blockers to provide proof of the specific and nonspecific binding components presented here. One study using a non-xanthine, selective A 2A receptor antagonist in development, vipadenant (previously known as BIIB014) has been reported [34] , and the study using preladenant (product in development with the similar mechanism of action) will be reported in the future.
Conclusions
The pilot PET studies with 11 C-SCH442416 demonstrated the quantifiability of A 2A receptor binding in striatal regions of the human brain. Despite the fast kinetics and the small contribution of specific binding to the total tissue activity, specific binding parameters can be estimated with spectral analysis. Further studies using other available selective A 2A receptor blockers, will be important to fully validate the assumption on which the calculation of the binding potential is based on.
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